431 related articles for article (PubMed ID: 29330094)
21. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.
Ma Y; McCarty SK; Kapuriya NP; Brendel VJ; Wang C; Zhang X; Jarjoura D; Saji M; Chen CS; Ringel MD
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1314-22. PubMed ID: 23709653
[TBL] [Abstract][Full Text] [Related]
22. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
23. The subcellular localization of type I p21-activated kinases is controlled by the disordered variable region and polybasic sequences.
Sun X; Su VL; Calderwood DA
J Biol Chem; 2019 Sep; 294(39):14319-14332. PubMed ID: 31391252
[TBL] [Abstract][Full Text] [Related]
24. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
[TBL] [Abstract][Full Text] [Related]
25. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
26. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD
Endocr Relat Cancer; 2010 Dec; 17(4):989-99. PubMed ID: 20817787
[TBL] [Abstract][Full Text] [Related]
27. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
28. p21-Activated kinase 1 (PAK1) in aging and longevity: An overview.
Amirthalingam M; Palanisamy S; Tawata S
Ageing Res Rev; 2021 Nov; 71():101443. PubMed ID: 34390849
[TBL] [Abstract][Full Text] [Related]
29. PAK signaling in cancer.
Ye DZ; Field J
Cell Logist; 2012 Apr; 2(2):105-116. PubMed ID: 23162742
[TBL] [Abstract][Full Text] [Related]
30. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.
Ong CC; Gierke S; Pitt C; Sagolla M; Cheng CK; Zhou W; Jubb AM; Strickland L; Schmidt M; Duron SG; Campbell DA; Zheng W; Dehdashti S; Shen M; Yang N; Behnke ML; Huang W; McKew JC; Chernoff J; Forrest WF; Haverty PM; Chin SF; Rakha EA; Green AR; Ellis IO; Caldas C; O'Brien T; Friedman LS; Koeppen H; Rudolph J; Hoeflich KP
Breast Cancer Res; 2015 Apr; 17(1):59. PubMed ID: 25902869
[TBL] [Abstract][Full Text] [Related]
31. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
32. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.
Prudnikova TY; Chernoff J
Small GTPases; 2017 Oct; 8(4):193-198. PubMed ID: 27427770
[TBL] [Abstract][Full Text] [Related]
33. p21-activated kinases and gastrointestinal cancer.
He H; Baldwin GS
Biochim Biophys Acta; 2013 Jan; 1833(1):33-9. PubMed ID: 23092728
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Potential of Targeting PAK Signaling.
Senapedis W; Crochiere M; Baloglu E; Landesman Y
Anticancer Agents Med Chem; 2016; 16(1):75-88. PubMed ID: 26081410
[TBL] [Abstract][Full Text] [Related]
35. Role of p21-activated kinases in cardiovascular development and function.
Kelly ML; Astsaturov A; Chernoff J
Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
[TBL] [Abstract][Full Text] [Related]
36. PAK signalling during the development and progression of cancer.
Radu M; Semenova G; Kosoff R; Chernoff J
Nat Rev Cancer; 2014 Jan; 14(1):13-25. PubMed ID: 24505617
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
Gul M; Fakhar M; Najumuddin ; Rashid S
PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.
Eswaran J; Li DQ; Shah A; Kumar R
Clin Cancer Res; 2012 Jul; 18(14):3743-9. PubMed ID: 22595609
[TBL] [Abstract][Full Text] [Related]
39. The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment.
Wang Y; Minden A
Cells; 2021 Dec; 10(12):. PubMed ID: 34944073
[TBL] [Abstract][Full Text] [Related]
40. Regulation of the p21-activated kinase (PAK) by a human Gbeta -like WD-repeat protein, hPIP1.
Xia C; Ma W; Stafford LJ; Marcus S; Xiong WC; Liu M
Proc Natl Acad Sci U S A; 2001 May; 98(11):6174-9. PubMed ID: 11371639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
